Ultragenyx (RARE) Jumped 7.5% on FDA Approval. Can a $2.7 Million Gene Therapy Become a Commercial Success?

Summary

Ultragenyx received FDA approval for a gene therapy candidate, resulting in a 7.5% stock price increase. The article raises questions about the commercial viability of the $2.7 million gene therapy.